Leaders of the Global Liquid Biopsy RevolutionAs pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD).SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.

Mutation Detection Sequence Analysis Oncology Molecular Diagnostics circulating tumor dna ctDNA liquid biopsy Plasma NGS Next Generation Sequencing digital PCR BEAMing Clinical Trials Safe-SeqS NGS CLIA GCP Cancer Molecular Testing Medicine Research IVD Kit